Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|June 14, 2011
2010 Top 200 generic drugs by retail dollars
Which drugs were most popular in 2010? Check out Drug Topics' list of the Top 200 generic drugs in 2010, ranked by retail dollars.
Advertisement
Advertisement
Related to this article
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
5